iShares Biotechnology ETF
896 hedge funds and large institutions have $5.32B invested in iShares Biotechnology ETF in 2024 Q1 according to their latest regulatory filings, with 102 funds opening new positions, 246 increasing their positions, 308 reducing their positions, and 66 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
0.29% more ownership
Funds ownership: 69.23% → 69.52% (+0.29%)
20% less repeat investments, than reductions
Existing positions increased: 246 | Existing positions reduced: 308
79% less call options, than puts
Call options by funds: $222M | Put options by funds: $1.07B
Holders
896
Holding in Top 10
11
Calls
$222M
Puts
$1.07B
Top Buyers
| 1 | +$141M | |
| 2 | +$92.2M | |
| 3 | +$65.7M | |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$57.3M |
| 5 |
Citigroup
New York
|
+$51.2M |
Top Sellers
| 1 | -$333M | |
| 2 | -$108M | |
| 3 | -$57.2M | |
| 4 |
IUHSA
Itau Unibanco Holding S.A.
Sao Paulo,
Brazil
|
-$29.2M |
| 5 |
MPM
MBB Public Markets
Chicago,
Illinois
|
-$18.8M |